After intraperitoneal injection of a TRPC3 agonist, the general condition, growth state, and lung development in the BPD + group significantly improved compared with the BPD group, but pulmonary edema and a small amount of inflammatory cell infiltration remained. This evidence concerns the gene TRPC3 and bronchopulmonary dysplasia.